Taro Pharmaceutical Industries Ltd (TARO) Stock

DelistedNYSE: TAROTaro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally.

42.97
Final close · Jun 20, 2024

TARO is no longer traded. Taro Pharmaceutical Industries was acquired by Sun Pharma on June 20, 2024.

Each TARO share was exchanged for $43.00 in cash. Prices on this page are historical; the last trade was June 20, 2024 at $42.97.

Taro Pharmaceutical Industries stock price history

Split-adjusted closes, 1993–2024

TARO final trading statistics

Final close
$42.97
Final trading day
Jun 20, 2024
Market cap at delisting
$1.62B
Shares outstanding
37.58M
Final 52-week range
$32.67 – $45.76
Avg. volume (final 3 mo.)
32,919
All-time high (split-adj.)
$149.92 · Feb 2015
All-time low (split-adj.)
$0.34 · Dec 1987
Return since IPO
+4673.9%
Beta
0.56
Book value / share
$47.70
Price / book
0.90
Final 52 wk
32.6745.76

Taro Pharmaceutical Industries earnings per share

Earnings per share

Taro Pharmaceutical Industries revenue & net income

RevenueNet income

Taro Pharmaceutical Industries annual financials

Taro Pharmaceutical Industries Ltd revenue, net income and EPS by fiscal year
Fiscal yearRevenueNet incomeEPS
FY2024$629.18M$53.9M$1.72
FY2023$572.95M$25.4M$0.67
FY2022$561.35M$58.3M$3.18
FY2021$548.97M-$400.7M-$10.11
FY2020$644.77M$244.2M$6.36

Last five fiscal years reported before the delisting; fiscal year ending March. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.

About Taro Pharmaceutical Industries Ltd

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

Taro Pharmaceutical Industries stock FAQ

What happened to Taro Pharmaceutical Industries stock?

Taro Pharmaceutical Industries was acquired by Sun Pharma on June 20, 2024. Shareholders received $43.00 in cash for each share. TARO stock stopped trading on the NYSE, with a final close of $42.97 on June 20, 2024.

What did Taro Pharmaceutical Industries shareholders receive?

Each TARO share was converted into $43.00 in cash. The deal was valued at about $348 million for the shares it did not already own.

Is TARO stock still trading?

No. TARO was delisted from the NYSE on June 20, 2024 and no longer trades on a U.S. exchange.

What was the last price of TARO stock?

TARO closed at $42.97 on its final trading day, June 20, 2024, for a market value of about $1.62B.

What were Taro Pharmaceutical Industries's revenue and earnings in its last full fiscal year?

Taro Pharmaceutical Industries reported revenue of $629.18M and net income of $53.9M in fiscal 2024, its last full year as a public company.

When did Taro Pharmaceutical Industries go public?

Taro Pharmaceutical Industries Ltd stock began trading on April 1, 1993.

Drug Manufacturers - Specialty & Generic stocks to research

All Healthcare stocks →